Veracyte, Inc.
Financials
Valuation Metrics
Veracyte, Inc.'s Market Cap is $3.58B. At end of 2025 it was $3.33B. Ranked #1641 of 3,112 in US market (top 53%), #582 of 1,445 on NASDAQ (top 40%), #96 of 206 in Health Care Equipment & Services (top 47%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.58B | US#1,641/3,112 Sec#96/206 |
| Revenue | $542M | US#2,311/3,112 Sec#145/206 |
| Net Income | $88M | US#1,655/3,112 Sec#82/206 |
| Total Assets | $1.44B | US#2,255/3,112 Sec#115/206 |
| Net Assets | $1.34B | US#1,559/3,112 Sec#81/206 |
| Employees | 755 | US#1,301/3,112 Sec#107/206 |
| Value | ||
| P/E | 40.66x | US#1,712/3,112 Sec#78/206 |
| P/B | 2.66x | US#1,536/3,112 Sec#89/206 |
| PEG | 0.13x | US#233/3,112 Sec#6/206 |
| P/S | 6.61x | US#2,467/3,112 Sec#173/206 |
| EV/EBITDA | 29.89x | US#2,170/3,112 Sec#117/206 |
| FCF Yield | 4.33% | US#1,442/3,112 Sec#79/206 |
| Profitability | ||
| ROE | 6.55% | US#1,706/3,112 Sec#82/206 |
| ROA | 6.13% | US#850/3,112 Sec#55/206 |
| Op. Margin | 12.45% | US#1,423/3,112 Sec#60/206 |
| Revenue Growth | 21.49% | US#695/3,112 Sec#42/206 |
| Earnings Growth | 307.36% | US#137/3,112 Sec#4/206 |
| Financial Health | ||
| Debt Ratio | 6.84% | US#68/3,112 Sec#3/206 |
| Total Debt | $39M | US#2,590/3,112 Sec#154/206 |
| FCF | $155M | US#1,475/3,112 Sec#89/206 |
| Cash | $263M | US#1,519/3,112 Sec#86/206 |
| Current Ratio | 9.31x | US#269/3,112 Sec#15/206 |
| Net Debt/EBITDA | -1.99x | US#178/3,112 Sec#13/206 |
| Performance | ||
| 1Y Return | 89.72% | US#395/3,112 Sec#36/206 |
| 1M Return | -21.43% | US#2,970/3,112 Sec#196/206 |
| From 52W High | -26.37% | US#2,005/3,112 Sec#138/206 |
| 1Y MDD | -39.23% | US#1,912/3,112 Sec#103/206 |
| Trading | ||
| Volume | 1,988,530 shares | US#890/3,112 Sec#56/206 |
| Trading Value | $91M | US#976/3,112 Sec#76/206 |
| Per Share | ||
| EPS | $0.84 | US#1,694/3,112 Sec#87/206 |
| BPS | $16.54 | US#1,397/3,112 Sec#79/206 |
Company Info
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.